Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western pharmaceutical companies and Chinese biotechs, multiple research firms suggest.
Large pharma companies have in-licensed nearly a third of their external molecules from Chinese
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/182762684/image_182762684.jpg?io=getty-c-w750
2025-01-18 14:56:17